Article
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.
Interventional cardiology clinics - 1 Oct 2024
Cavallari Larisa H, Coons James C
Abstract excerpt
The CYP2C19 enzyme metabolizes clopidogrel, a prodrug, to its active form. Approximately 30% of individuals inherit a loss-of-function (LoF) polymorphism in the CYP2C19 gene, leading to reduced formation of the active clopidogrel metabolite. Reduced clopidogrel effectiveness has been well documented in patients with an LoF allele following an acute coronary syndrome or percutaneous coronary intervention....
Topics
Join the communities discussing this publication.